These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20134142)

  • 1. [Cost benefit analysis for prophylactic use of itraconazole versus fluconazole after hematopoietic stem cell transplantation].
    Ota S; Wada A; Kosugi M; Matsuoka S; Asanuma S; Fujii S; Noguchi S; Nakata M; Imai K; Hirano T; Kobayashi N; Ogasawara M; Kiyama Y; Kasai M
    Rinsho Ketsueki; 2010 Jan; 51(1):63-8. PubMed ID: 20134142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
    Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
    Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
    Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
    Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
    Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
    McCoy D; Depestel DD; Carver PL
    Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
    Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
    Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy.
    Grigull L; Kuehlke O; Beilken A; Sander A; Linderkamp C; Schmid H; Seidemann K; Sykora KW; Schuster FR; Welte K
    Pediatr Transplant; 2007 May; 11(3):261-6. PubMed ID: 17430480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Glasmacher A; Prentice AG
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
    Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
    Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.
    Sánchez-Ortega I; Patiño B; Muñoz C; Arnan M; Peralta T; Clopés A; de Sevilla AF; Duarte RF
    J Med Econ; 2013; 16(6):736-43. PubMed ID: 23541251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
    Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
    J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
    Vardakas KZ; Michalopoulos A; Falagas ME
    Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
    van Burik JA; Ratanatharathorn V; Stepan DE; Miller CB; Lipton JH; Vesole DH; Bunin N; Wall DA; Hiemenz JW; Satoi Y; Lee JM; Walsh TJ;
    Clin Infect Dis; 2004 Nov; 39(10):1407-16. PubMed ID: 15546073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation.
    Annaloro C; Oriana A; Tagliaferri E; Bertolli V; Della Volpe A; Soligo D; Ibatici A; Pozzoli E; Lambertenghi Deliliers GL
    Haematologica; 1995; 80(6):512-7. PubMed ID: 8647515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
    Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
    Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
    Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
    Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection.
    Manfredi R; Mastroianni A; Coronado OV; Chiodo F
    Arch Intern Med; 1997 Jan; 157(1):64-9. PubMed ID: 8996042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.